AC
BCRX icon

Amici Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Amici Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100,000
Closed -$441K – 64
2016
Q3 		$441K Hold
100,000
– – 0.12% 77
2016
Q2 		$284K Hold
100,000
– – 0.05% 107
2016
Q1 		$283K Buy
+100,000
New +$443K 0.03% 100

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Amici Capital's BCRX Position: Q4 2016 in Review

Amici Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2016, closing a stake of 100,000 shares — an estimated $441K sold.

Amici Capital first reported a position in BCRX in Q1 2016 and held it in 3 quarters. The position peaked at $441K in Q3 2016. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

  • Amici Capital reported no remaining BioCryst Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Amici Capital sold 100,000 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $441K.
  • Amici Capital first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Amici Capital's BioCryst Pharmaceuticals position peaked at $441K in Q3 2016.
  • 112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on Amici Capital's 13F filing for Q4 2016, filed 14 Feb 2017.